Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review.
Saved in:
| Title: | Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review. |
|---|---|
| Authors: | Li F; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Department of Oncology, Tianjin Beichen Hospital, Tianjin, China., Xu Y; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China., Wang Y; Department of Oncology, Tianjin Beichen Hospital, Tianjin, China., Mu N; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China., Liu M; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China., Feng W; Department of Oncology, Tianjin Beichen Hospital, Tianjin, China., Xue Y; Department of Basic Research, Suzhou Lanma Biotechnology Co., Suzhou, China., Wu S; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China., Wang X; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China., Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Houston, TX, United States., Ma C; Department of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.; Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Apr 23; Vol. 16, pp. 1789442. Date of Electronic Publication: 2026 Apr 23 (Print Publication: 2026). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
